Literature DB >> 10087008

Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice.

K Yokogawa1, Y Higashi, I Tamai, M Nomura, N Hashimoto, H Nikaido, J Hayakawa, K Miyamoto, A Tsuji.   

Abstract

We kinetically analyzed the disposition of L-carnitine of juvenile visceral steatosis (JVS) mice compared with that of normal mice to elucidate the mechanism of the systemic L-carnitine deficiency of JVS mice. There were significant differences in the plasma concentration-time course of total radioactive carnitine (L-[3H]carnitine, [acetyl-3H]carnitine, and other [acyl-3H]carnitines) between normal and JVS mice after a single i.v. or p.o. administration of L-[3H]carnitine (250 ng/kg). The oral bioavailability of L-[3H]carnitine in JVS mice (0.341) was about half of that in normal mice (0.675). The cumulative urinary excretion of total radioactive carnitine in JVS mice was about 10-fold more than that in normal mice, and the total clearance of unchanged L-[3H]carnitine for JVS mice (6.70 ml/min) was significantly higher than that for normal mice (2.45 ml/min). The distribution volume at the steady state of unchanged L-[3H]carnitine in JVS mice (1.10 liters/kg) was significantly smaller than that in normal mice (8.16 liters/kg). At 4 h after an i.v. administration, the apparent tissue-to-plasma concentration ratios of unchanged L-[3H]carnitine for various tissues of JVS mice, except for brain, were about one half to one 20th of those in normal mice. In conclusion, this in vivo disposition kinetic study of L-carnitine supports the previous in vitro finding that the L-carnitine transporter is absent or functionally deficient in JVS mice because the renal reabsorption, the intestinal absorption, and the apparent tissue-to-plasma concentration ratios in JVS mice are significantly lower than those in normal mice. The JVS mouse should be a useful experimental model for studying carnitine deficiency diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10087008

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Absorbing competition for carnitine.

Authors:  P M Taylor
Journal:  J Physiol       Date:  2001-04-15       Impact factor: 5.182

Review 2.  Active efflux across the blood-brain barrier: role of the solute carrier family.

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  NeuroRx       Date:  2005-01

3.  Na+- and Cl--coupled active transport of carnitine by the amino acid transporter ATB(0,+) from mouse colon expressed in HRPE cells and Xenopus oocytes.

Authors:  T Nakanishi; T Hatanaka; W Huang; P D Prasad; F H Leibach; M E Ganapathy; V Ganapathy
Journal:  J Physiol       Date:  2001-04-15       Impact factor: 5.182

4.  Up-regulation of carnitine transporters helps maintain tissue carnitine levels in carnitine deficiency induced by pivalic acid.

Authors:  N Okudaira; M Fujigaki; T Nakayoshi; I Komiya; Y Sugiyama
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

5.  Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+).

Authors:  Sonne R Srinivas; Puttur D Prasad; Nagavedi S Umapathy; Vadivel Ganapathy; Prem S Shekhawat
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-09-13       Impact factor: 4.052

6.  Regulation of Genes Involved in Carnitine Homeostasis by PPARα across Different Species (Rat, Mouse, Pig, Cattle, Chicken, and Human).

Authors:  Robert Ringseis; Gaiping Wen; Klaus Eder
Journal:  PPAR Res       Date:  2012-10-23       Impact factor: 4.964

Review 7.  Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology.

Authors:  Sophia L Samodelov; Gerd A Kullak-Ublick; Zhibo Gai; Michele Visentin
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.